Home
Kenneth Dickstein's picture

Kenneth Dickstein

Professor
  • E-mailKenneth.Dickstein@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2014. The relationship between markers of extracellular cardiac matrix turnover: Infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. European Heart Journal. 395-402.
  • Show author(s) 2014. The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients. European Journal of Heart Failure. 289-299.
  • Show author(s) 2014. Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. International Journal of Cardiology. 360-367.
  • Show author(s) 2013. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. European Heart Journal. 30-38.
  • Show author(s) 2013. Sildenafil in Heart Failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. European Journal of Heart Failure. 119-122.
  • Show author(s) 2013. Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. International Journal of Cardiology. 1094-1101.
  • Show author(s) 2013. Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy. European Journal of Heart Failure. 1419-1428.
  • Show author(s) 2013. Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction. International Journal of Cardiology. 212-218.
  • Show author(s) 2013. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. European Journal of Heart Failure. 1267-1276.
  • Show author(s) 2013. Global variation in quality of care among patients hospitalized with acute heart failure in an international trial findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). Circulation. Cardiovascular Quality and Outcomes. 534-542.
  • Show author(s) 2013. Clustering of 37 circulating biomarkers by exploratory factor analysis in patients following complicated acute myocardial infarction. International Journal of Cardiology. 729-735.
  • Show author(s) 2013. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. New England Journal of Medicine. 1395-1405.
  • Show author(s) 2013. Cardiac resynchronization therapy improves minute ventilation/carbon dioxide production slope and skeletal muscle capillary density without reversal of skeletal muscle pathology or inflammation. Europace. 857-864.
  • Show author(s) 2012. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. European Journal of Heart Failure. 1257-1264.
  • Show author(s) 2012. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. European Journal of Heart Failure. 1401-1409.
  • Show author(s) 2012. Myocardial Connective Tissue Growth Factor (CCN2/CTGF) Attenuates Left Ventricular Remodeling after Myocardial Infarction. PLOS ONE. 15 pages.
  • Show author(s) 2012. Increased interleukin-1 beta levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Journal of Internal Medicine. 267-276.
  • Show author(s) 2012. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic HeartFailure 2012 of the European Society of Cardiology. Developed in collaborationwith the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 803-869.
  • Show author(s) 2012. ESC Guidelines for the management of acute myocardial infarction in patientspresenting with ST-segment elevation. European Heart Journal. 2569-2619.
  • Show author(s) 2012. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic HeartFailure 2012 of the European Society of Cardiology. Developed in collaborationwith the Heart Failure Association (HFA) of the ESC. European Heart Journal. 1787-1847.
  • Show author(s) 2012. A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment. Chinese Medical Journal. 3868-3874.
  • Show author(s) 2012. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 1236-1286.
  • Show author(s) 2012. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm. 1524-1576.
  • Show author(s) 2011. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. International Journal of Cardiology. 277-282.
  • Show author(s) 2011. Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 115-126.
  • Show author(s) 2011. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. European Journal of Heart Failure. 107-114.
  • Show author(s) 2010. Update of ESC guidelines regarding usage of devices in patients with heart failure-2010. Kardiologia polska. S475-S486.
  • Show author(s) 2010. The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: A retrospective cohort study. International Journal of Cardiology. 228-233.
  • Show author(s) 2010. Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes Lessons Learned and Directions Forward. Circulation: Heart Failure. 314-325.
  • Show author(s) 2010. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. European Journal of Heart Failure. 239-248.
  • Show author(s) 2010. 2010 Focused Update of ESC Guidelines on device therapy in heart failure. European Journal of Heart Failure. 1143-1153.
  • Show author(s) 2010. 2010 Focused Update of ESC Guidelines on device therapy in heart failure. Europace. 1526-1536.
  • Show author(s) 2009. The European cardiac resynchronization therapy survey. European Heart Journal. 2450-2460.
  • Show author(s) 2009. The Chemokine Network in Relation to Infarct Size and Left Ventricular Remodeling Following Acute Myocardial Infarction. American Journal of Cardiology. 1179-1183.
  • Show author(s) 2009. Six-Minute Walk Test and Cardiopulmonary Exercise Testing in Patients With Chronic Heart Failure A Comparative Analysis on Clinical and Prognostic Insights. Circulation: Heart Failure. 549-555.
  • Show author(s) 2009. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). American Heart Journal. 271-277.
  • Show author(s) 2009. Rationale and design of Ferinject((R)) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure. 1084-1091.
  • Show author(s) 2009. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. European Heart Journal. 1331-1339.
  • Show author(s) 2009. Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarction. International Journal of Cardiology. 229-232.
  • Show author(s) 2009. Microvascular obstruction is a major determinant of infarct healing and subsequent left ventricular remodelling following primary percutaneous coronary intervention. European Heart Journal. 1978-1985.
  • Show author(s) 2009. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. European Heart Journal. 1229-1236.
  • Show author(s) 2009. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. European Journal of Heart Failure. 1143-1151.
  • Show author(s) 2009. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine. 2436-2448.
  • Show author(s) 2009. Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. American Heart Journal. 91-96.
  • Show author(s) 2009. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet. 1840-1848.
  • Show author(s) 2009. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. European Heart Journal. 478-486.
  • Show author(s) 2009. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal. 1187-1194.
  • Show author(s) 2009. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. European Heart Journal. 1180-1186.
  • Show author(s) 2009. B-type natriuretic peptide is related to histological skeletal muscle abnormalities in patients with chronic heart failure. International Journal of Cardiology. 358-362.
  • Show author(s) 2008. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. The Lancet. 547-553.
  • Show author(s) 2008. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. European Journal of Heart Failure. 140-148.
  • Show author(s) 2008. Effect of exercise training on chromogranin A and relationship to N-ANP and inflammatory cytokines in patients with chronic heart failure. International Journal of Cardiology. 117-120.
  • Show author(s) 2008. Design of the Heart failure Endpoint evaluation of AII-Antagonist Losartan (HEAAL) study in patients intolerant to ACE-inhibitor. European Journal of Heart Failure. 899-906.
  • Show author(s) 2008. A randomised trial of a pre-synaptic stimulator of DA(2)-dopaminergic and alpha(2)-adrenergic receptors on morbidity and mortality in patients with heart failure. European Journal of Heart Failure. 89-95.
  • Show author(s) 2007. Usefulness of either or both left and right bundle branch block at baseline or during follow-up for predicting death in patients following acute myocardial infarction. American Journal of Cardiology. 647-650.
  • Show author(s) 2007. Unrecognized glycometabolic disturbance as measured by hemoglobin A(1c) is associated with a poor outcome after acute myocardial infarction. American Heart Journal. 470-476.
  • Show author(s) 2007. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: Relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. Journal of Cardiac Failure. 843-849.
  • Show author(s) 2007. Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. American Journal of Cardiology. 1104-1114.
  • Show author(s) 2006. The impact of morbid events on survival following hospitalization for complicated myocardial infarction. European Journal of Heart Failure. 74-80.
  • Show author(s) 2006. The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure. European Journal of Heart Failure. 628-633.
  • Show author(s) 2006. Sex-based short- and long-term survival in patients following complicated myocardial infarction. European Heart Journal. 2177-2183.
  • Show author(s) 2006. Rapid implementation of therapeutic hypothermia in comatose out-of-hospital cardiac arrest survivors. Acta Anaesthesiologica Scandinavica. 1277-1283.
  • Show author(s) 2006. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. American Heart Journal. 927e1-927e6.
  • Show author(s) 2006. Mannose binding lectin and soluble Toll-lilke receptor 2 in heart failure following acute myocardial infarction. Journal of Cardiac Failure. 659-663.
  • Show author(s) 2005. Soluble CD40 ligand in acute and chronic heart failure. European Heart Journal. 1101-1107.
  • Show author(s) 2005. Soluble CD40 ligand in acute and chronic heart failure. European Heart Journal. 1101-1117.
  • Show author(s) 2005. Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. American Journal of Medicine. 752-758.
  • Show author(s) 2005. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAL experience. European Heart Journal. 350-356.
  • Show author(s) 2005. Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to prognosis: an OPTIMAAL substudy. Journal of Cardiac Failure. 492-497.
  • Show author(s) 2005. Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. Journal of the American College of Cardiology. 2018-2021.
  • Show author(s) 2005. Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction? Nature Clinical Practice Cardiovascular Medicine. 440-441.
  • Show author(s) 2005. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. European Heart Journal. 650-61.
  • Show author(s) 2005. Exercise training in congestive heart failure. A review of the current status. Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy. 275-286.
  • Show author(s) 2005. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). American Heart Journal. 123-131.
  • Show author(s) 2004. The data monitoring experience in the MOXCON trial. European Heart Journal. 174-178.
  • Show author(s) 2004. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New England Journal of Medicine. 1285-1295.
  • Show author(s) 2004. Prognostic value of osteoprotegerin in heart failure following acute myocardial infarction. Journal of the American College of Cardiology. 1970-1976.
  • Show author(s) 2004. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. Journal of the American College of Cardiology. 1970-1976.
  • Show author(s) 2004. Effects of losartan and captopril on morbidity and mortality after acute MI. Cardiology Review. 23-29.
  • Show author(s) 2004. Effect of single doses of SLV306, an inhibitor of both neutral enclopepticlase and enclothelin-converting enzyme, on pulmonary pressures in congestive heart failure. American Journal of Cardiology. 237-240.
  • Show author(s) 2004. Effect of exercise training in patients with heart failure: a pilot study on autonomous balance assessed by heart rate variability. Journal of Cardiovascular Risk. 162-167.
  • Show author(s) 2004. Effect of exercise training in patients with heart failure: a pilot study on autonomic balance assessed by heart rate variability. Journal of Cardiovascular Risk. 162-167.
  • Show author(s) 2004. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. American Journal of Cardiology. 603-606.
  • Show author(s) 2004. Comparison of mortality rates after acute myocardial infarction in smokers versus nonsmokers. American Journal of Cardiology. 632-636.
  • Show author(s) 2003. Prognostic usefulness of an increase of N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. American Journal of Cardiology. 91-94.
  • Show author(s) 2003. Prognostic usefulness of an increase in N-terminal proatrial natriuretic peptide during exercise in patients with chronic heart failure. American Journal of Cardiology. 91-94.
  • Show author(s) 2003. Plasma chromogranin A concentration as an indicator of long-term mortality after acute myocardial infarction. American Journal of Medicine. 25-30.
  • Show author(s) 2003. Neurohumoral inhibition in heart failure; is there no limit? European Heart Journal. 1705-1706.
  • Show author(s) 2003. N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. International Journal of Cardiology. 197-205.
  • Show author(s) 2003. N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. International Journal of Cardiology. 197-205.
  • Show author(s) 2003. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. American Journal of Medicine. 25-30.
  • Show author(s) 2003. Association between plasma chromogranin A and long-term mortality after myocardial infarction. American Journal of Medicine. 25-30.
  • Show author(s) 2002. Prioritering av sykehusobduksjon. Tidsskrift for Den norske legeforening. 2787-2790.
  • Show author(s) 2002. How do heart failure patients die? European Heart Journal. D59-D65.
  • Show author(s) 2002. For the OPTIMAAL trial: losartan or captopril after acute myocardial infarction. The Lancet. 1885.
  • Show author(s) 2002. Effects of losatan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. The Lancet. 752-760.
  • Show author(s) 2002. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. The Lancet. 752-760.
  • Show author(s) 2002. Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. International Journal of Cardiology. 25-32.
  • Show author(s) 2002. Characteristics and prognostic impact of plasma fibrin monomer (soluble fibrin) in patients with coronary artery disease. Blood Coagulation and Fibrinolysis. 301-308.
  • Show author(s) 2001. The role of losartan in the management of patients with heart failure. Clinical Therapeutics. 1456-1477.
  • Show author(s) 2001. How long should ACE inhibitors be given to patients following myocardial infarction: Implications of HOPE. Controlled Clinical Trials. 151-154.
  • Show author(s) 2001. Fibrin monomer (soluble fibrin) as a marker of coagulation activation in patients with acute chest pain syndromes. Clinical Chemistry.
  • Show author(s) 2001. Effect of simvastatin in preventing progression of carotid artery stenosis. American Journal of Cardiology. 643-646.
  • Show author(s) 2001. Effect of aerobic exercise training on plasma levels of tumor necosis factor alpha in patients with heart failure. American Journal of Cardiology. 805-808.
  • Show author(s) 2001. ELITE II and ValHeft; Together what do they tell us? Controlled Clinical Trials. 240-243.
  • Show author(s) 2001. Digitalis ved hjertesvikt - fortsatt et aktuelt behandlingsprinsipp? Tidsskrift for Den norske legeforening. 212-214.
  • Show author(s) 2001. Comparison of baseline data, initial course, and management: Losartan vs. Captopril following acute myocardial infarction (The OPTIMAAL Trial). American Journal of Cardiology. 766-771.
  • Show author(s) 2001. Comparison of baseline data, Initial course, and mannagment: Losartan Versus captopril following acute myocardial infarction (The OPTIMAAL Trial). American Journal of Cardiology. 766-771.
  • Show author(s) 2001. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. American Journal of Ophthalmology. 626-632.
  • Show author(s) 2001. Assessing the effect of exercise training in men with heart failure. Comparison of maximal, submaximal and endurance protocols. European Heart Journal. 684-692.
  • Show author(s) 2001. AllAs in congestive heart failure: Insights from ELITE II and ValHeft. Receptors in Cardiovascular Disease. 7.
  • Show author(s) 2000. The use of angiotensin II receptor antagonists in heart failure. Tidsskrift for Den norske legeforening. 817-821.
  • Show author(s) 2000. The Effects of Chronic, Sustained-release Moxonidine Therapy on Clinical and Neurohumoral Status in Patients with Heart Failure. International Journal of Cardiology. 167-176.
  • Show author(s) 2000. The Effects of Chronic, Sustained-release Moxonidine Therapy on Clinical and Neurohumoral Status in Patients with Heart Failure. International Journal of Cardiology. 167-176.
  • Show author(s) 2000. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. The Lancet. 1582-1587.
  • Show author(s) 2000. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Survival Study - ELITE II. The Lancet. 1582-1587.
  • Show author(s) 2000. Plasma chromogranin A is an independent predictor of survival after acute myocardial infarction. European Heart Journal. 584.
  • Show author(s) 2000. Plasma brain natriuretic peptide as a prognostic indicator in patients with preserved left ventricular systolic function after acute myocardial infarction. Circulation. 609.
  • Show author(s) 2000. Pharmacotherapy following myocardial infarction - a review of current treatment practices. Exp Opin Pharmacother. 1105-1116.
  • Show author(s) 2000. Pharmacotherapy following myocardial infarction - a review of current treatment practices. Expert Opinion on Pharmacotherapy. 1105-1116.
  • Show author(s) 2000. Losartan vs. Captopril in patients following Acute Myocardial Infarction: The OPTIMAL Trial Design. Receptors in Cardiovascular Disease. 4-9.
  • Show author(s) 2000. Losartan vs. Captopril in patients following Acute Myocardial Infarction: The OPTIMAL Trial Design. Receptors in Cardiovascular Disease. 4-9.
  • Show author(s) 2000. Improvements in quality of life of symptomatic heart failure patients treated long-term with losartan and captopril: the ELITE II quality of life substudy. European Heart Journal. 464.
  • Show author(s) 2000. Exercise training in heart failure. Time to go beyond surrogate endpoints. European Journal of Heart Failure. 5-6.
  • Show author(s) 2000. Exercise training in heart failure. Time to go beyond surrogate endpoints. European Journal of Heart Failure. 5-6.
  • Show author(s) 2000. Er øyeblikkelig hjelp-innleggelser i medisinks avdeling avhengig av været? Tidsskrift for Den norske legeforening. 3678-3679.
  • Show author(s) 2000. Effects of moxonidine, a novel imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Journal of the American College of Cardiology. 398-404.
  • Show author(s) 2000. Effects of moxonidine, a novel imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Journal of the American College of Cardiology. 398-404.
  • Show author(s) 2000. Effects of exercise training on maximal and submaximal endurance capacity in men with congestive heart failure. European Journal of Heart Failure. In press.
  • Show author(s) 2000. Effect of simvastatin in preventing progression of carotid artery stenosis. American Journal of Cardiology. 17-20.
  • Show author(s) 2000. Effect of aerobic exercise training on cytokine levels in patients with congestive heart failure. European Heart Journal. 234.
  • Show author(s) 2000. Bruk av angiotensin II - reseptorblokkere ved hjertesvikt. Tidsskrift for Den norske legeforening. 817-821.
  • Show author(s) 2000. Are emergency medical admissions dependent on the weather? Tidsskrift for Den norske legeforening. 355-357.
  • Show author(s) 2000. Angiotensin II antagonists are superior to ACE inhibitors. David versus Golitah. European Journal of Heart Failure. 235-236.
  • Show author(s) 2000. Angiotensin II antagonists are superior to ACE inhibitors. David versus Golitah. European Journal of Heart Failure. 235-236.
  • Show author(s) 1999. Kronisk hjertesvikt - forslag til handlingsprogram. Tidsskrift for Den norske legeforening. 3427-3431.
  • Show author(s) 1999. Comparison of the effects of Losartan and Captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL Trial Design. American Journal of Cardiology. 1-5.
  • Show author(s) 1997. Treatment of heart failure with beta-adrenergic blocking drugs. Tidsskrift for Den norske legeforening. 526-528.
  • Show author(s) 1997. Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. Journal of Cardiac Failure. 83-89.
  • Show author(s) 1997. Effects of angiotensin II receptor blockage on N- terminal proatrial natriuretic factor plasma levels in chronic heart failure. Journal of Cardiac Failure. 75-81.
  • Show author(s) 1997. Digitalis - et gammelt, men stadig aktuelt medikament. Therapia medica. 16-18.
  • Show author(s) 1997. Calcium channel blockers in heart failure. Tidsskrift for Den norske legeforening. 2329-2332.
  • Show author(s) 1997. Betablokkerbehandling av hjertesviktpasienter. Tidsskrift for Den norske legeforening. 526-528.
  • Show author(s) 1996. Pro-atrial natriuretisk faktor i plasma er prediktiv for klinisk status hos hjertesviktpasienter. Tidsskrift for Den norske legeforening. 1562-1566.
  • Show author(s) 1993. The effect of early converting enzyme inhibition on neurohumoral activycation in acute myocardial infarction. International Journal of Cardiology. 37-45.
Academic lecture
  • Show author(s) 2008. C-reactive protein, infarct size, microvascular obstruction and left ventricular remodeling following acute myocardial infarction.
  • Show author(s) 2005. Living with an implantable cardioverter defibrillator: A qualitative study from one Norwegian centre.
  • Show author(s) 2002. The role of angiotensin II antagonists in heart failure and following myocardial infarction.
  • Show author(s) 2002. State of the art management of myocardial infarction.
  • Show author(s) 2002. Results of recent trials in patients with heart failure following myocardial infarction.
  • Show author(s) 2002. Outpatient heart failure management programs – 4 models New markers of heart failure Determinants of long-term prognosis in heart failure Emerging therapies for heart failure.
  • Show author(s) 2002. Modern Aspects of Heart Failure Management. Recent Acheivements and Future Directions.
  • Show author(s) 2002. Controlling the course of disease in the post-myocardial infarction patient: the OPTIMAAL trial.
  • Show author(s) 2002. Comparison of the Effects of Losartan and Captopril on Mortality and Morbidity in patients following Acute Myocardial Infarction: The OPTIMAAL Trial.
  • Show author(s) 2002. Clinical implications of losartan in the OPTIMAAL study.
  • Show author(s) 2002. Beta-blockers should be withdrawn in decompensated heart failure patients.
  • Show author(s) 2002. Angiotensin II antagonists; are they established therapy in heart failure?
  • Show author(s) 2002. ARBs are as good as ACE inhibitors.
  • Show author(s) 2001. Effect of exercise training on muscle fibre characteristics in patients with heart failure.
  • Show author(s) 1996. N-terminal probrain natriuretic peptide - a new marker of cardiac function and prognosis.
Abstract
  • Show author(s) 2013. The association between heart rate, pulse pressure and clinical outcomes in 16503 patients with myocardial infarction complicated by signs of heart failure or left ventricular dysfunction. European Heart Journal. 349-349.
  • Show author(s) 2013. Early discharge (< 3 days) following primary PCI is safe in low risk patients. European Heart Journal. 246-246.
  • Show author(s) 2013. ESC Heart Failure Guidelines 2012-a review. Journal of Cardiac Failure. S106-S107.
  • Show author(s) 2010. Smokers spend shorter time in hospital than non-smokers following complicated AMI. European Heart Journal. 683-683.
  • Show author(s) 2010. Predicting Adverse Effects during Angiotensin Receptor Blocker Treatment in Heart Failure: Results from the HEAAL Trial. Journal of Cardiac Failure. S73-S74.
  • Show author(s) 2010. Peripheral artery disease as a predictor of outcome in high-risk MI patients: pooled analysis from the high risk MI database initiative (pooled data from CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT). European Heart Journal. 604-604.
  • Show author(s) 2010. NT-proBNP is a potent prognostic marker in patients with type 2 diabetes hospitalized for acute coronary syndrome - a DIGAMI 2 sub study. European Heart Journal. 514-515.
  • Show author(s) 2010. Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction and prevents ischemic heart failure. European Heart Journal. 314-314.
  • Show author(s) 2010. Intravenous ferric carboxymaltose improves quality of life in patients with chronic heart failure and iron deficiency regardless the presence of anaemia: an analysis from the FAIR-HF study. European Heart Journal. 233-233.
  • Show author(s) 2010. Early increase in Stromelysin-1 levels is related to infarct size and predicts long-term LV remodelling following STEMI. European Heart Journal. 192-193.
  • Show author(s) 2010. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Circulation. 2217-2217.
  • Show author(s) 2009. Circulating Markers of Collagen Turnover Following ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention Predict Infarct Size and Left Ventricular Volumes, Estimated by Serial Cardiac Magnetic Resonance Imaging for up to 1 Year. Circulation. S818-S818.
  • Show author(s) 2007. The relationship between N-terminal B-type natriuretic peptide and circulating markers of extracellular cardiac remodelling in patients following complicated myocardial infarction. European Journal of Heart Failure. 10-11.
  • Show author(s) 2004. What's new in the management of heart failure? Atherosclerosis Supplements.
  • Show author(s) 2004. Total mortality and sudden cardiac death are predicted by both left and right bundle branch block at baseline and during follow-up after complicated myocardial infarction. Circulation. A1032-A1032.
  • Show author(s) 2004. The relationship between the extent of myocardial scarring and left ventricular ejection fraction assessed by cardiac magnetic resonance in 57 patients with previous myocardial infarction. European Heart Journal. 599-599.
  • Show author(s) 2004. The longitudinal profile of markers of cardiac extracellular matrix turnover in patients following acute myocardial infarction. European Heart Journal.
  • Show author(s) 2004. Relative impact of renal function on circulating levels of brain-type natriuretic peptide an N-terminal-pro-brain-type natriuretic peptide in patients with postinfarction heart failure. European Heart Journal. 292-292.
  • Show author(s) 2004. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction. The OPTIMAL experience. European Heart Journal. 299-299.
  • Show author(s) 2004. Moderate alcohol use is associated with reduced cardiovascular risk in patients following complicated acute myocardial infarction. JACC. 1153-1173.
  • Show author(s) 2004. Hemoglobin levels predict survival and hospitalization after a complicated acute myocardial infarction: Results from the OPTIMAAL study. Circulation. 574-575.
  • Show author(s) 2004. Haemoglobin levels predict survival and hospitalisation after a complicated acute myocardial infarction: results from the OPTIMAAL study. European Heart Journal. 305-305.
  • Show author(s) 2004. Effect of hypo- and hyperkalemia on mode of death in patients with heart failure following myocardial infarction. European Heart Journal.
  • Show author(s) 2003. Serial high-sensitivity CRP measurements and long-term prognosis in postinfarction heart failure. The OPTIMAAL neurohormonal substudy. Circulation.
  • Show author(s) 2003. Serial high-sensitivity CRP measurements and long-term prognosis in post-infarction heart failure. The OPTIMAAL neurohormonal study. Circulation. 692-692.
Academic literature review
  • Show author(s) 2020. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 407-477.
  • Show author(s) 2019. Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. The Lancet. 1045-1055.
  • Show author(s) 2016. Telerehabilitation in heart failure patients: The evidence and the pitfalls. International Journal of Cardiology. 408-413.
  • Show author(s) 2015. The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International Journal of Cardiology. 256-264.
  • Show author(s) 2013. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure. 1082-1094.
  • Show author(s) 2012. The High-Risk Myocardial Infarction Database Initiative. Progress in cardiovascular diseases. 362-366.
  • Show author(s) 2010. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure. 423-433.
  • Show author(s) 2008. Successful treatment of heart failure with devices requires collaboration. European Journal of Heart Failure. 1229-1235.
  • Show author(s) 2008. Overview of emerging pharmacologic agents for acute heart failure syndromes. European Journal of Heart Failure. 201-213.
  • Show author(s) 2008. Guidelines 2008 European Society of Cardiology on the diagnosis and treatment of acute and chronic heart failure. Kardiologia polska. S389-S454.
  • Show author(s) 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal. 2388-442.
  • Show author(s) 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Journal of Heart Failure. 933-989.
  • Show author(s) 2008. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal. 2388-2442.
  • Show author(s) 2007. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 684-694.
  • Show author(s) 2005. Diagnosis and assessment of the heart failure patient: the cornerstone of effective management. European Journal of Heart Failure. 303-308.

More information in national current research information system (CRIStin)